What is HRTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for HRTX?

P/E (TTM) is n/a and 52-week range is $0.26 to $1.58 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s HRTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for HRTX?

The company profile lists revenue (TTM) near $150M, net income (TTM) near $-3.39B, EPS (TTM) near $-0.19 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Heron Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cary, North Carolina, US, 189.3M shares outstanding, ISIN US4277461020 when available from company profile and filing metadata.

Chartloom

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in Cary, North Carolina and currently employs 128 full-time employees. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.

Employees

128

Website

www.herontx.com/

IPO

1987-08-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)